Investors watch China’s ‘two sessions’ for clues on property overhaul



Ahead of China’s annual legislative meetings – typically a window into Beijing’s top-level policy agenda – this is the seventh entry in a series examining the complex economic recalibration driving China’s growth philosophy and its wide-ranging implications for local governments, financial investors and private enterprises.

Investors and policy watchers will be looking to this week’s meetings of China’s national legislature and top political advisory body – also known as the “two sessions” – for signals on whether Beijing will advance efforts to reshape the country’s embattled property sector.

Calls to “accelerate the development of a new model for real estate” had featured prominently in government work reports delivered at recent local-level “two sessions” across provinces and cities, according to research compiled by the China Index Academy.

The think tank said its review of local policy priorities offered an early indication of the themes likely to surface at this year’s national meetings.

The proposed shift – first raised two years ago – marks a departure from the traditional “high debt, high leverage, high turnover” model that fuelled two decades of rapid expansion but left developers dangerously exposed when liquidity tightened.

Instead, officials were signalling a more sustainable, “dual-track” system that emphasised higher-quality commercial housing alongside a larger role for government-backed affordable homes, analysts said, citing statements issued after high-level policy meetings.

  • Related Posts

    Biotech-led boom as 8 China firms flock to Hong Kong’s thriving stock market

    Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the…

    Continue reading
    Multinational pharmaceutical companies to benefit from new China guidelines: analysts

    The State Council, China’s cabinet, has published guidelines on innovative drug pricing that a bank analyst has described as “the most significant” in a decade, as they aim to reward…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *